TECN Tecan Group AG
Tecan Group AG provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally. It operates in two segments: Life Sciences Business and Partnering Business. The company offers liquid handling and automation, microplate readers and washers, software, consumables, sequencing reagents, immunoassays and antibodies, and Tecan Labwerx, an end-to-end automation solution. It also provides PARAMIT, a contract design and manufacturing service. Tecan Group AG has a strategic collaboration with NVIDIA Corporation to develop AI-enabled platform for data-driven laboratories to help discoveries and lab productivity. The company was founded in 1980 and is headquartered in Männedorf, Switzerland.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Tecan Group (SWX: TECN)
›
Tecan Group (SWX: TECN) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 3,000 employees.
The shares were at 243.80 CHF on 19 November 2026, up 79.8% over 52 weeks. Its 52-week range is 110.60 CHF to 278.00 CHF: the price is 12.3% below the high and 120.4% above the low.
Its market capitalisation is 3.00B CHF. It pays a dividend yielding 1.27% (it pays out 61% of its earnings), against a median of 0.93% among the dividend payers in that peer group.
Tecan Group reports return on equity of -9.6%, an operating margin of 4.9% and revenue down 2.7% year over year.
It holds more cash than debt, a net cash position of 10.16M CHF. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 8 analysts cover the stock, with an average rating of Buy; their mean price target of 222.72 CHF is 8.6% below the current price. The next earnings report is expected on 10 March 2027.